Portfolio

Molecular Partners

Develops a proprietary new class of drugs called DARPins - "Antibody v. 2.0"


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Transaction Summary

  • Completed a $100M IPO in 2014
  • Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness